NasdaqGM:SUPNPharmaceuticals
Supernus Pharmaceuticals (SUPN) Could Be 24% Undervalued If Its CNS Pipeline Delivers
Recent Share Performance and Business Snapshot
Supernus Pharmaceuticals (SUPN) has drawn investor attention after a recent move in its share price, with the stock up 0.9% over the past day and 2.6% over the past week.
Over the past month, Supernus Pharmaceuticals is up 7.9%. However, the stock is down 4.8% over the past 3 months and down 3.2% year to date, while the 1 year total return stands at 46.5%.
See our latest analysis for Supernus Pharmaceuticals.
The recent 1 month share price return...